Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
June 27 2022 - 9:00AM
Business Wire
- By signing the Kigali Declaration, Gilead
joins the global community committed to ending neglected tropical
diseases by 2030 -
Gilead Sciences today announced that the company has signed onto
the Kigali Declaration on neglected tropical diseases (NTDs) which
succeeds the London Declaration on NTDs. It was launched on the
margins of the Commonwealth Heads of Government Meeting (CHOGM), at
a high-level session that was attended by Heads of State, other
global dignitaries, industry partners and global community as part
of a joint malaria and NTDs Summit. This high-level political
declaration is an important milestone for the World Health
Organization’s 2030 road map which includes global targets to
prevent, control and in some cases eliminate 20 diseases and
disease groups by 2030.
“Gilead has a long history of supporting the control and
elimination of neglected tropical diseases. In signing the Kigali
Declaration, we are reaffirming our commitment as part of our
ongoing efforts to advance global health equity,” said Daniel
O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The
progress made against NTDs to date demonstrates the power of
collaboration and unrelenting focus.”
As Gilead marks 30 years of partnership with the World Health
Organization (WHO) to end visceral leishmaniasis (VL), the company
also commits to driving private sector engagement towards the
Sustainable Development Goals for health and global partnership to
achieve not only the control of NTDs but the elimination of their
root causes, as well. In particular, Gilead will:
- Continue its product donation to the VL elimination program led
by WHO between 2023- and 2027.
- Support and invest in innovative global initiatives that will
address health equity.
- Spearhead and contribute to a broad stakeholder dialogue
driving pharmaceutical sector engagement and investment in tackling
environmental issues causing NTDs, such as climate change and lack
of access to clean water.
Find more information about the 2030 Neglected Tropical Disease
road map here:
https://www.who.int/teams/control-of-neglected-tropical-diseases/ending-ntds-together-towards-2030
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis and cancer. Gilead operates in more than 35
countries worldwide, with headquarters in Foster City,
California.
Gilead and the Gilead logo are trademarks of
Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit
the company’s website at www.gilead.com , follow Gilead on Twitter
(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220624005468/en/
Jacquie Ross, Investors (408) 656-8793 Bahar Turkoglu, Media +44
7768 555517
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024